We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Prostate Cancer Data Shine at ASCO Conference
Johnson & Johnson (J&J), Merck and AstraZeneca are presenting positive phase 3 data supporting drugs for castration-resistant prostate cancer at this week’s meeting of the American Society of Clinical Oncology in San Francisco.